Literature DB >> 32086990

Taiwan is on track of accelerating hepatitis C elimination by 2025.

Grace Hui-Min Wu1,2, Raoh-Fang Pwu1,3, Shih-Chung Chen4, Ding-Shinn Chen5,6,7.   

Abstract

Entities:  

Year:  2020        PMID： 32086990     DOI： 10.1111/liv.14412

Source DB:  PubMed          Journal:  Liver Int        ISSN： 1478-3223            Impact factor:   5.828


× No keyword cloud information.
  3 in total

1.  Comparison of 8- versus 12-weeks of glecaprevir/pibrentasvir for Taiwanese patients with hepatitis C and compensated cirrhosis in a real-world setting.

Authors:  Yung-Hsin Lu; Chung-Kuang Lu; Chun-Hsien Chen; Yung-Yu Hsieh; Shui-Yi Tung; Yi-Hsing Chen; Chih-Wei Yen; Wei-Lin Tung; Kao-Chi Chang; Wei-Ming Chen; Sheng-Nan Lu; Chao-Hung Hung; Te-Sheng Chang
Journal:  PLoS One       Date:  2022-08-18       Impact factor: 3.752

2.  Collaborative Referral Model to Achieve Hepatitis C Micro-Elimination in Methadone Maintenance Treatment Patients during the COVID-19 Pandemic.

Authors:  Chi-Ming Tai; Chun-Kai Huang; Te-Chang Changchien; Po-Chun Lin; Deng-Wu Wang; Ting-Ting Chang; Hsue-Wei Chan; Tzu-Haw Chen; Cheng-Hao Tseng; Chih-Cheng Chen; Chia-Ta Tsai; Yu-Ting Sie; Yung-Chieh Yen; Ming-Lung Yu
Journal:  Viruses       Date:  2022-07-27       Impact factor: 5.818

3.  Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison.

Authors:  Chun-Ting Chen; Ming-Ying Lu; Meng-Hsuan Hsieh; Pei-Chien Tsai; Tsai-Yuan Hsieh; Ming-Lun Yeh; Ching-I Huang; Yi-Shan Tsai; Yu-Min Ko; Ching-Chih Lin; Kuan-Yu Chen; Yu-Ju Wei; Po-Yao Hsu; Cheng-Ting Hsu; Tyng-Yuan Jang; Ta-Wei Liu; Po-Cheng Liang; Ming-Yen Hsieh; Zu-Yau Lin; Chung-Feng Huang; Jee-Fu Huang; Chia-Yen Dai; Wan-Long Chuang; Yu-Lueng Shih; Ming-Lung Yu
Journal:  World J Gastroenterol       Date:  2022-01-14       Impact factor: 5.742
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.